Flamingo Therapeutics Announces Participation in Upcoming Investor and Industry Conferences
2024-04-04
临床2期临床1期siRNA
LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, April 4, 2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced its participation in the following upcoming investor and industry conferences:
23rd Annual Needham Virtual Healthcare Conference, being held in a virtual format, April 8-11, 2024. Company management will meet with investors in one-on-one meetings during the conference.
BioTrinity London conference, being held April 23-24, 2024, in London, United Kingdom. Stephane van Rooijen, MD, MBA, Chief Executive Officer, will be presenting during the Oncology R&D Spotlight session at 9:15 AM on Tuesday, April 23, 2024.
BioEquity Europe24, being held May 12-14, 2024, in San Sebastian, Spain and online. Company management will meet with potential partners during the conference. Dr. van Rooijen will give a company presentation during the congress.
About Flamingo Therapeutics
Flamingo is pioneering RNA-targeted therapies for oncology with a clinical-stage pipeline targeting undruggable transcription factors and long non-coding RNAs. Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, Abrdn (formerly funds managed by Tekla Capital Management LLC) and VIB.
Flamingo has initiated a Phase 2 trial 'PEMDA-HN' evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC), and a Phase 1 investigator-initiated study in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
For more information on Flamingo, please visit:
https://flamingotx.com
PEMDA-HN on clinicaltrials.gov:
https://clinicaltrials.gov/study/NCT05814666
Danvatirsen monotherapy followed by combination with venetoclax in relapsed/ refractory AML and MDS on clincaltrials.gov:
https://classic.clinicaltrials.gov/ct2/show/NCT05986240
Please engage with us on LinkedIn:
https://www.linkedin.com/company/flamingo-therapeutics.
Flamingo Media and Investor Contact:
Amy Conrad
Juniper Point
(858) 366-3243
[email protected]
SOURCE Flamingo Therapeutics
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。